Now, the nasal spray can be used on its own ... Those requirements can make it more difficult to access Spravato. Some people ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition affecting around 8.3% of adults. This treatment provides rapid relief from ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray ... want you to know about Spravato, plus potential side effects to be aware of.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray ... effects, it’s long used medically as an anesthetic. Prior to Spravato’s approval ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...